Empagliflozin-associated Armanni-Ebstein lesions in IgA nephropathy
Kidney International · 2026-08 · 110 (2) · 494-495
DOI: 10.1016/j.kint.2025.12.032 ↗Kurz gefasst
Fallbericht in der Zeitschrift Kidney International, 2026-08. Verfasst von Zhou Qin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Nephrology, Zhejiang Univ…. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Gefördert von: Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents, Research and Development.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Institute of Nephrology, Zhejiang University, Hangzhou, China; Key Laboratory of Kidney Disease Prevention a…
- Department of Urology, Center for Regeneration and Aging Medicine, The Fourth Affiliated Hospital of School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yi…
Förderung
- Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
- Research and Development
Zitieren
APA
Qin, Z., Weiqiang, L., Dajin, C., & Rending, W. (2026). Empagliflozin-associated Armanni-Ebstein lesions in IgA nephropathy. Kidney International, 110(2), 494-495. https://doi.org/10.1016/j.kint.2025.12.032
Vancouver
Qin Z, Weiqiang L, Dajin C, Rending W. Empagliflozin-associated Armanni-Ebstein lesions in IgA nephropathy. Kidney International. 2026;110(2):494-495. doi:10.1016/j.kint.2025.12.032
BibTeX
@article{Qin2026,
author = {Qin, Zhou and Weiqiang, Lin and Dajin, Chen and Rending, Wang},
title = {Empagliflozin-associated Armanni-Ebstein lesions in IgA nephropathy},
journal = {Kidney International},
year = {2026},
volume = {110},
number = {2},
pages = {494--495},
doi = {10.1016/j.kint.2025.12.032}
}
EUVIMED